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ublichealthandsmokingareolden-
emies because smoking is among
the10leadingcausesofillhealthon
a global scale and is also possible to pre-
vent, as repeatedly reported (1). In both
developed and developing countries,
smoking takes its heavy toll of lives every
year,bothdirectlyandindirectly,through
exposure to passively inhaled tobacco
smoke (2) or via feto-placental effects.
Much research efforts have been devoted
to ﬁnding news ways to help the individ-
ual smoker quit the harmful habit, not
only based on individual (3) or group-
based support activities (4), as supported
bythewholehealthcareteam,butalsoon
ways of prescribing both older and newer
drugstosupportsmokingcessation.Even
if nicotine replacement therapy (5) in its
various forms has been around for almost 3
decadesandtheatypicalantidepressantbu-
propion(6)for10years,newtargetdrugs
are constantly being developed to support
the addicted smoker in quitting perma-
nently. Such drugs may be useful for very
large groups of addicted smokers who have
tried the other ways to quit in vain. One
example is varenicline, a partial nicotine re-
ceptor agonist that has been proven suc-
cessful in randomized controlled trials,
both for smoking cessation and for relapse
prevention (7–10). The effect is more pro-
nounced than recorded by use of nicotine
replacement therapy or bupropion.
Otherwaysmightalsoexisttoachieve
smokingcessation,suchastheuseofacu-
puncture, hypnosis, or psychopharmaco-
logical approaches, but these remedies
are less well proven and therefore not
truly evidence based.
NEW DEVELOPMENT FOR
OLD DRUGS— However, older
drug preparations are developing. New
faster delivery nicotine replacement drug
delivery systems (11) bear the promise of
addressing a broader list of indications,
including treatment of nicotine with-
drawal during temporary abstinence and
long-termnicotinemaintenance.Another
approach is preventive immunization
againstnicotineaddiction.Thesevaccines
will need to demonstrate efﬁcacy and
long-termsafetyandimprovecertaincon-
sumer acceptability characteristics (e.g.,
frequency of injections required) before
theycanbecomewidelyusedtherapies.A
recent study showed potential beneﬁts
with immunization for nicotine depen-
dence (12), but the beneﬁcial effects has
largely been conﬁned to those with high
antibody titers, a group that so far has not
been possible to identify beforehand. Still
the best hope for improved treatment re-
sults comes from combining existing and
newpharmacotherapieswitheffectivebe-
havioral therapy, both individually and
based on group session cessation—a con-
cept that was reported to be successful in
a randomized study from Swedish pri-
mary health care in the 1990s (13).
IS HARM REDUCTION OF
TOBACCO USE AN
ACCEPTABLE STRATEGY? — One
more controversial issue that has pro-
vokedaheateddebateiswhetherSwedish
tobacco snuff (“snus”) should be recom-
mended for heavy smokers to make them
avoid inhalation and thereby decrease
their disease risk in general (14). Snus is
mostly used in Scandinavia, but similar
noninhaled nicotine products are also
available in other countries. Should snus
be recommended even if this habit might
cause health problems by itself, e.g., an
increased risk of pancreatic cancer (15)?
One argument in favor of using snus for
harm reduction is that a linear relation-
ship has been shown for the number of
daily cigarettes smoked and the risk of
myocardial infarction, according to the
global INTERHEART study in 15,000
subjects with MI and their matched con-
trol subjects (16).
HARMFUL EFFECTS OF
SMOKING IN ALL AGE-
GROUPS— Smoking seems to harm
human biology irrespective of age, even if
exposuretotobaccoisbelievedtobemost
deleterious in fetal or perinatal life when
maternal smoking will increase the risk of
fetallossaswellasnumeroushealthprob-
lems in the offspring (17). Earlier studies
have suggested that the male fetus is even
more susceptible than the female fetus to
smoking in the pregnant mother (18).
The negative effect on fetal growth from
maternal smoking was reported to affect
the male fetus proportionally more than
the female fetus (19). However, few long-
term follow-up studies are available to
study the consequences past the child-
hood period. Maternal smoking during
pregnancy is a risk factor that could affect
offspring health, but is also a risk factor
for subsequent nicotine dependence
among these subjects (20). In Helsing-
borg, a community in southern Sweden
with previously widespread smoking
habits, all pregnant women were rou-
tinely asked to state their smoking habits
during the period 1961–1965 (21). After
long-term follow-up for 30 years, the risk
of early mortality was increased in male
offspring (21).
Anothervulnerableperiodissmoking
in young adolescence when the organ de-
velopment can be impaired, especially
lung function, more so in girls than in
boys (22). Most physicians will also take
an active stand against tobacco use in
middle-aged patients, especially after a
cardiovascular event, to improve second-
ary prevention. In elderly smoking sub-
jects,thereisoftenamorerelaxedattitude
toward this habit among health care
workers.Someofthemarguethatifaper-
son has lived a long life as a smoker with-
out serious adverse health effects, advice
to quit this habit should no longer be a
focus. On the other hand, it has been
shown that many medical conditions in
the elderly can improve, creating in-
creased quality of life after smoking ces-
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artery disease and chronic obstructive
pulmonary disease. Furthermore, some
elderly people with predementia or cog-
nitive impairment might forget about
burning cigarettes and thereby cause
harm to themselves or to others after ac-
cidentalﬁre-setting.Therefore,thereexist
good clinical arguments to stop smoking
in the overwhelming majority of patients
and also in supposedly healthy individu-
als irrespective of their age. One excep-
tion could potentially be patients with a
fatal disease such as terminal cancer or
other serious life-threatening conditions
if they are not willing to give up their
habit.
No other global risk factor is so com-
mon and so dangerous for most ordinary
citizens as the hazardous habit of smok-
ing. Certain chronic conditions such as
chronic obstructive pulmonary disease,
coronary heart disease, and even type 2
diabetes (23) are the worst consequences
of smoking besides cancer. However, in
early or even fetal life, the exposure to
passive smoking in the environment or
via a pregnant mother who smokes poses
a great health risk that should be taken
seriously. Future health research should
focus on new ways of helping the tobacco
addict to quit the habit, including newly
developed central nervous system–active
drugsandevenvaccines.Adeeperunder-
standing of the pathophysiological mech-
anismsinvolvedintheimpactofsmoking
on, for example, glucose metabolism and
diabetes is also needed (23). However, in
the end, these individual approaches will
not be sufﬁcient if they are not combined
with national goals for tobacco reduction
and control (24) by use of price politics,
taxation, legislation with sales restriction
to minors, and international agreements
toreducetheproductionoftobaccoprod-
ucts in both developing and more devel-
oped countries.
A CHALLENGE TO HEALTH
WORKERS TO HELP
SMOKERS QUIT— According to
recentCochranereports,simpleadviceby
physicians and other health workers has
often a small effect on cessation rates, but
canhavealargeimpactonabroaderscale
if offered to many smokers. Additional
maneuvers appear to have only a small
effect, although more intensive interven-
tions are marginally more effective than
minimal interventions (3). Groups for
smoking cessation are better than self-
help and other less intensive intervention
(4).Thereisnotenoughevidenceontheir
effectiveness, or cost-effectiveness, com-
pared with intensive individual counsel-
ing.Theinclusionofskillstrainingtohelp
smokers avoid relapse appears to be use-
ful, although the evidence is limited.
These interventions should be supported
by modern effective drug therapy, with
more intensity the higher the risk in the
individual patient.
Finally, according to the most re-
cently released U.S. guidelines, it is stated
that 1) both counseling and medications
shouldbeprovidedwheneverpossible,2)
thereisstrongerevidencethanbeforethat
counselingisacriticalpartoftobaccoces-
sation, and lastly 3) individual, group,
and telephone counseling are effective,
and their effectiveness increases with
treatment intensity. Physicians are com-
monlynotexpertsineducationandcoun-
seling why there is a need to engage all
members of the health care team to do
better for achieving smoking cessation in
their at-risk patients, especially in those
with diabetes. This strategy also includes
the important activities of health educa-
tors, nurses, and pharmacists, to name
a few.
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